Among these, human epidermal growth factor receptor 2 (HER2)-positive breast cancer is recognized for its aggressive clinical course, and the advent of HER2-targeted therapies has significantly improved outcomes [6–8]. The gene discussed is ERBB2; the disease is breast carcinoma.